查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1390755

胃輕癱藥物市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Gastroparesis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

概要

2022年全球胃輕癱藥物市場規模達62億美元。展望未來， IMARC Group預計到2028年市場規模將達到82億美元，2022-2028年複合年成長率（CAGR）為4.77%。

胃輕癱，也稱為胃麻痺，是一種影響胃部肌肉正常和自發性運動的疾病。它會干擾消化過程，導致噁心、嘔吐、腹痛以及維持血糖水平和營養吸收的問題。目前在醫師指導下使用藥物治療，如多潘立酮、甲氧氯普胺、紅黴素、苯海拉明、昂丹司瓊、丙氯拉嗪等。

胃輕癱藥物市場趨勢：

由於快速城市化、久坐的生活方式以及經常飲酒和吸煙的人數不斷增加，全球糖尿病盛行率顯著上升。這與相對更容易患胃輕癱的老年人口的增加相結合，是推動市場成長的關鍵因素之一。此外，胃輕癱藥物可透過提高收縮頻率來幫助增強胃腸蠕動。因此，它們被廣泛用於治療特發性胃輕癱，這種疾病會導致嚴重嘔吐、噁心和上腹部疼痛。再加上因外科手術傷害模糊神經及其分支而導致胃輕癱的人數大幅增加，也促進了市場的成長。此外，領先的製造商不斷資助研發 (R&D) 項目，為現有藥物治療引入新方法。他們也正在開發先進且有效的藥物，可以透過鼻腔給藥，用於患有胃輕癱症狀的人，這創造了良好的市場前景。其他主要因素，包括醫療保健基礎設施的改善和對使用者友善藥物的需求不斷增加，預計將推動市場的成長。

本報告回答的關鍵問題

  • 2022年全球胃輕癱藥物市場規模？
  • 2023-2028年全球胃輕癱藥物市場的預期成長率為何？
  • COVID-19 對全球胃輕癱藥物市場有何影響？
  • 推動全球胃輕癱藥物市場的關鍵因素是什麼？
  • 根據疾病類型，全球胃輕癱藥物市場的細分如何？
  • 根據藥物類別，全球胃輕癱藥物市場的細分如何？
  • 根據配銷通路，全球胃輕癱藥物市場的細分如何？
  • 全球胃輕癱藥物市場的重點區域有哪些？
  • 全球胃輕癱藥物市場的主要參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球胃輕癱藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：依疾病類型分類的市場

  • 糖尿病胃輕癱
    • 市場走向
    • 市場預測
  • 特發性胃輕癱
    • 市場走向
    • 市場預測
  • 術後胃輕癱
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：按藥物類別分類的市場細分

  • 促動力劑
    • 市場走向
    • 市場預測
  • 止吐劑
    • 市場走向
    • 市場預測
  • 肉毒桿菌注射
    • 市場走向
    • 市場預測

第 8 章：按配銷通路分類的市場區隔

  • 醫院和診所
    • 市場走向
    • 市場預測
  • 藥局
    • 市場走向
    • 市場預測
  • 網路商店
    • 市場走向
    • 市場預測

第 9 章：按地區分類的市場區隔

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Abbvie Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • Evoke Pharma
    • Medtronic plc
    • Neurogastrx Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
Product Code: SR112023A4608

Abstract

The global gastroparesis drugs market size reached US$ 6.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.2 Billion by 2028, exhibiting a growth rate (CAGR) of 4.77% during 2022-2028.

Gastroparesis, also known as stomach paralysis, is a medical condition that affects the normal and spontaneous movement of the muscles in the stomach. It interferes with the digestion process and causes nausea, vomiting, abdominal pain, and problems with maintaining blood sugar levels and nutrition absorption. At present, it is treated under the guidance of doctors using drugs, such as domperidone, metoclopramide, erythromycin, diphenhydramine, ondansetron, and prochlorperazine.

Gastroparesis Drugs Market Trends:

Due to rapid urbanization, sedentary lifestyles and the growing number of individuals who drink and smoke regularly, there is a significant rise in the prevalence of diabetes across the globe. This, in confluence with the increasing geriatric population, which is relatively more susceptible to developing gastroparesis, represents one of the key factors bolstering the growth of the market. In addition, gastroparesis drugs aid in enhancing gastrointestinal motility by improving the frequency of contraction. As a result, they are extensively being utilized for treating idiopathic gastroparesis, which causes severe vomiting, nausea, and upper abdominal pain. This, along with a considerable rise in the number of individuals developing gastroparesis after the vague nerve and its branches are damaged via surgical operations, are also contributing to market growth. Furthermore, leading manufacturers are continuously funding research and development (R&D) projects to introduce new approaches to the existing drug therapy. They are also developing advanced and effective drugs that can be administered via the nasal cavity for individuals who are experiencing symptoms of gastroparesis, which is creating a favorable market outlook. Other major factors, including the improving healthcare infrastructure and the escalating demand for user-friendly drugs, are anticipated to impel the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global gastroparesis drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on disease type, drug class and distribution channel.

Breakup by Disease Type:

Diabetic Gastroparesis

Idiopathic Gastroparesis

Post-surgical Gastroparesis

Others

Breakup by Drug Class:

Prokinetic Agents

Antiemetic Agents

Botulinum Toxin Injections

Breakup by Distribution Channel:

Hospitals and Clinics

Pharmacies

Online Stores

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Theravance Biopharma.

Key Questions Answered in This Report

  • 1. What was the size of the global gastroparesis drugs market in 2022?
  • 2. What is the expected growth rate of the global gastroparesis drugs market during 2023-2028?
  • 3. What has been the impact of COVID-19 on the global gastroparesis drugs market?
  • 4. What are the key factors driving the global gastroparesis drugs market?
  • 5. What is the breakup of the global gastroparesis drugs market based on the disease type?
  • 6. What is the breakup of the global gastroparesis drugs market based on the drug class?
  • 7. What is the breakup of the global gastroparesis drugs market based on the distribution channel?
  • 8. What are the key regions in the global gastroparesis drugs market?
  • 9. Who are the key players/companies in the global gastroparesis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastroparesis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Diabetic Gastroparesis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Idiopathic Gastroparesis
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Post-surgical Gastroparesis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Prokinetic Agents
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antiemetic Agents
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Botulinum Toxin Injections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbvie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bausch Health Companies Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Becton Dickinson and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Boston Scientific Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Evoke Pharma
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Neurogastrx Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sanofi S.A.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Theravance Biopharma
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Gastroparesis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastroparesis Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Gastroparesis Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Gastroparesis Drugs Market: Breakup by Disease Type (in %), 2022
  • Figure 5: Global: Gastroparesis Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 6: Global: Gastroparesis Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Gastroparesis Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Gastroparesis Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Gastroparesis Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Gastroparesis Drugs (Prokinetic Agents) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Gastroparesis Drugs (Prokinetic Agents) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Gastroparesis Drugs (Antiemetic Agents) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Gastroparesis Drugs (Antiemetic Agents) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Gastroparesis Drugs (Hospitals and Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Gastroparesis Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Gastroparesis Drugs (Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Gastroparesis Drugs (Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Gastroparesis Drugs (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Gastroparesis Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: North America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: North America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: United States: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: United States: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Canada: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Canada: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Asia-Pacific: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Asia-Pacific: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: China: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: China: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Japan: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Japan: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: India: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: India: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: South Korea: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: South Korea: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Australia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Australia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Indonesia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Indonesia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Europe: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Europe: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Germany: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Germany: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: France: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: France: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: United Kingdom: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: United Kingdom: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Italy: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Italy: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Spain: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Spain: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Russia: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Russia: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Latin America: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Latin America: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Brazil: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Brazil: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Mexico: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Mexico: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Middle East and Africa: Gastroparesis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Middle East and Africa: Gastroparesis Drugs Market: Breakup by Country (in %), 2022
  • Figure 76: Middle East and Africa: Gastroparesis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Global: Gastroparesis Drugs Industry: SWOT Analysis
  • Figure 78: Global: Gastroparesis Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Gastroparesis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastroparesis Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Gastroparesis Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 3: Global: Gastroparesis Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 4: Global: Gastroparesis Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Gastroparesis Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Gastroparesis Drugs Market: Competitive Structure
  • Table 7: Global: Gastroparesis Drugs Market: Key Players